HepatologyNews.net

Hepatology Xagena

Search results for "HCV genotype 1"

Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of Ribavirin ( Rebetol ) achieved sustained vira ...


Interim data from the ongoing C-WORTHY study, a phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus ( H ...


The standard treatment for hepatitis C virus ( HCV ) infection is Interferon, which is administered subcutaneously and can have troublesome side effects.Researchers have evaluated Sofosbuvir ( Sovaldi ...


There is a need for Interferon-free treatment regimens for hepatitis C virus ( HCV ) infection. The goal of a study was to evaluate ABT-450, a potent HCV NS3 protease inhibitor, combined with low-dose ...


All-oral combination therapy is desirable for patients with chronic hepatitis C virus ( HCV ) infection. Researchers evaluated Daclatasvir ( an HCV NS5A replication complex inhibitor ) plus Sofosbuvir ...


Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus ( HCV ) infection.In the phase 2b, randomized, open-label trial of Faldaprevir ( a proteas ...


The stability and propagation of hepatitis C virus ( HCV ) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 ( miR-122 ). Miravirsen is a locked nucleic ...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin has showed efficacy against the hepatitis C ...


Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented at the International Liver Congress 2014 showed that Simeprevir ( Olysio )150 mg once-daily for 12 weeks in comb ...


The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected ...


Effective treatment for hepatitis C virus ( HCV ) genotype 1 infection in patients who have not had a sustained virologic response to prior Interferon-based therapy represents an unmet medical need. ...


In this phase 3 trial researchers have evaluated the efficacy and safety of the Interferon-free combination of ABT-450 with Ritonavir ( ABT-450/r ), Ombitasvir ( also known as ABT-267 ), Dasabuvir ( a ...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in patients who also have cirrhosis. Researchers have evaluated th ...


In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor Sofosbuvir and the NS5A inhibitor Ledipasvir resulted in high rates of sustained virologic response a ...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also known as ABT-267 ) plus the nonnucleoside polymerase inhibitor D ...